BRD2 and cancer: Antimüllerian hormone allows for measurement of ovarian reserve because it is consistent throughout menstrual cycles even when patients are taking hormonal contraception, whereas FSH can fluctuate.51 For cancer survivors aged 25 years or older who have undergone gonadotoxic treatment, AMH in conjunction with FSH is recommended to identify premature ovarian insufficiency.52 For individuals with AYA in particular, AMH and FSH, combined with menstrual pattern, provide a more accurate assessment of ovarian reserve than menstrual pattern alone.24,33